ADAP - GSK to transfer back cancer drug programs to Adaptimmune

• Adaptimmune Therapeutics ( NASDAQ: ADAP ) on Tuesday said that GSK ( NYSE: GSK ) was transferring back cancer therapy programs NY-ESO and PRAME.
• In 2014 the two companies signed a collaboration and license agreement, for up to five programs. In 2017, GSK exercised its option to exclusively license the right to develop and commercialize NY-ESO SPEAR T-cell therapy program, after which two more targets including PRAME, were nominated.
• Adaptimmune said it is expected that that the license agreement will terminate and GSK will not have any rights to nominate any additional targets.
• The terms of the transfer are being negotiated, the company added.
• Adaptimmune noted that GSK will deliver data from an ongoing phase 2/potential registrational trial with lete-cel in sarcoma with final data expected in late 2023.
• Adaptimmune said it will continue to prioritize and focus on its lead MAGE-A4 franchise while deciding an optimal development path for PRAME and NY-ESO assets.

For further details see: